Help
Subscribe


Submit Videos to GastroHep Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Test-based strategy vs empiric dose escalation in unresponsive Crohn's disease

A study in the latest issue of Clinical Gastroenterology & Hepatology reports that a test-based strategy is more cost effective than empiric dose escalation for patients with Crohn's disease who lose responsiveness to infliximab.

News image

Patients with Crohn's disease who become unresponsive to therapy with tumor necrosis factor antagonists are managed initially with either empiric dose escalation or testing-based strategies.

The comparative cost effectiveness of these 2 strategies is unknown.

Dr Fernando Velayos from California, USA investigated whether a testing-based strategy is more cost effective than an empiric dose-escalation strategy.

The researchers compared 2 cohorts of patients with Crohn's disease evaluating the outcomes for the 2 strategies over a 1-year time period.

The research team assessed that the incremental cost-effectiveness ratio of the empiric strategy was expressed as cost per quality-adjusted life-year gained, compared with the testing-based strategy.

The team performed a 1-way, probabilistic, and prespecified secondary analyses.

Cost-effectiveness ratio of the empiric strategy ranged to more than $5 million per quality-adjusted life-year gained
Clinical Gastroenterology and Hepatology

The team of doctors reported that the testing strategy yielded similar quality-adjusted life-year compared with the empiric strategy but was less expensive.

In sensitivity analyses, the incremental cost-effectiveness ratio of the empiric strategy ranged from $500,000 to more than $5 million per quality-adjusted life-year gained.

The researchers observed that similar rates of remission and response were achieved through differential use of available interventions.

The testing-based strategy resulted in a higher percentage of surgeries and lower percentage use of high-dose biological therapy.

Dr Velayos's team commented, "A testing-based strategy is a cost-effective alternative to the current strategy of empiric dose escalation for managing patients with Crohn's disease who have lost responsiveness to infliximab."

"The basis for this difference is lower cost at similar outcomes."

Clin Gastroenterol and Hepatol 2013: 11(6): 654-666
28 June 2013

Go to top of page Email this page Email this page to a colleague

 02 July 2015

Advanced search
 02 July 2015 
Anastomotic leak and cancer cancer
 02 July 2015 
Ulcerative colitis prognosis after thiopurines withdrawal
 02 July 2015 
Health care use by IBD children
 01 July 2015 
Missed gastric cancers
 01 July 2015 
Probiotics in IBD
 01 July 2015 
Oral mechanical bowel preparation
 30 June 2015 
Glucocorticoids and peptic ulcer bleeding
 30 June 2015 
Split-dose preparations vs day-before bowel cleansing regimens
 30 June 2015 
NSAIDs and hearburn symptoms
 29 June 2015 
Rescue therapy in ulcerative colitis
 29 June 2015 
Prevention of pancreatitis after ERCP
 29 June 2015 
Advances in autoimmune pancreatitis
 26 June 2015 
Dietary fibre–microbiota interactions
 26 June 2015 
Gastritis in celiac disease
 26 June 2015 

Gene polymorphism in alcoholic liver disease

 25 June 2015 
Fecal microbiota in pediatric IBD
 25 June 2015 
Vitamin D level and primary biliary cirrhosis
 25 June 2015 
Persistent organ failure in acute cholangitis patients
 24 June 2015 
Fatigue scales for IBD
 24 June 2015 
Mucosal healing tests in ulcerative colitis
 24 June 2015 
Environmental risk in IBD
 23 June 2015 
Marker associated with endoscopic lesion in Crohn's
 23 June 2015 
Body composition in children with IBD
 23 June 2015 
Medical vs nurse endoscopists
 22 June 2015 
Gene polymorphism associated with increased liver enzymes
 22 June 2015 
Treatment of uncomplicated acute appendicitis
 22 June 2015 
Solid organ cancers after liver transplant
 19 June 2015 
Causes of death in HBV
 19 June 2015 
Lifetime benefits of increased adenoma detection rates
 19 June 2015 
Acid-suppressive therapy before anti-reflux surgery
 18 June 2015 
Endoscopic activity in symptomatic IBD patients
 18 June 2015 
Regimens for H. pylori eradication
 18 June 2015 
Risk for dyspepsia
 17 June 2015 
NAFLD risk in celiac disease
 17 June 2015 
Non-invasive markers of advanced liver fibrosis
 17 June 2015 
Patients’ and clinicians’ perception of pouch dysfunction
 16 June 2015 
Risk score for hepatocellular carcinoma screening
 16 June 2015 
Esophageal food bolus impaction
 16 June 2015 
Evaluating lymph node metastasis for rectal cancer
 15 June 2015 
Low-cost colonoscopy training
 15 June 2015 
Determining dysbiosis in IBS or IBD
 15 June 2015 
Light alcohol consumption and NAFLD
 12 June 2015 
Smoking and disease course in IBD
 12 June 2015 
Hep D in a Hep B endemic area
 12 June 2015 
Patient-orientated internet information in ulcerative colitis
 11 June 2015 
Physical inactivity and NAFLD
 11 June 2015 
Esophageal stricture after endoscopic resection
 11 June 2015 
Guideline based screening strategies for hepatitis
 10 June 2015 
Cost-effectiveness of HCV treatment in liver disease
 10 June 2015 
Abdominoperineal excision for low rectal cancer
 10 June 2015 
Pediatric chronic Hep C
 09 June 2015 
Bile acid malabsorption in IBS
 09 June 2015 
Racial differences in celiac disease
 09 June 2015 
Conversion from laparoscopic to open colorectal cancer resection
 08 June 2015 
Short sleep duration and NAFLD
 08 June 2015 
Heritability in inflammatory bowel disease
 08 June 2015 
Eosinophilic esophagitis
 05 June 2015 
In-hospital mortality in patients with lower GI bleeding
 05 June 2015 
Scoring system for microscopic colitis
 05 June 2015 
H. pylori and myocardial infarction

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2015 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us